RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1424 participants.
Also called NCT06195540
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,424 participants
- Sponsor
- Registry
-
NCT06195540 -
2023-509905-62-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT06195540. Randomized; single masking; primary purpose prevention. Start 2024-07-19 (actual); primary completion 2028-11-19 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
- Acronym
- RIVACAST
- Condition
- Venous Thromboembolism
- Condition
- Deep Vein Thrombosis
- Condition
- Pulmonary Embolism
- Condition
- Lower Limb Trauma
- Condition
- Thromboprophylaxis
- Condition
- Immobilisation
- Intervention (Drug)
- Rivaroxaban 10 MG
- Intervention (Drug)
- Low Heparin Molecular Weight
- Lead sponsor
- University Hospital, Angers
Record details
- Record id
cardio:ct-nct06195540- Content hash
02252d225a7115c5d0101154769ba08af7e4356e1bb60bc7000940cce165dfe1